PYC Therapeutics Ltd (AU:PYC) — Market Cap & Net Worth
Market Cap & Net Worth: PYC Therapeutics Ltd (PYC)
PYC Therapeutics Ltd (AU:PYC) has a market capitalization of $517.68 Million (AU$731.64 Million) as of May 2, 2026. Listed on the AU stock exchange, this Australia-based company holds position #12359 globally and #313 in its home market, demonstrating a -5.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PYC Therapeutics Ltd's stock price AU$1.23 by its total outstanding shares 597258697 (597.26 Million). Analyse cash efficiency ratio of PYC Therapeutics Ltd to see how efficiently the company converts income to cash.
PYC Therapeutics Ltd Market Cap History: 2015 to 2026
PYC Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows growth from $53.08 Million to $517.68 Million (24.12% CAGR).
Index Memberships
PYC Therapeutics Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$1.97 Trillion | 0.03% | #226 of 495 |
Weight: PYC Therapeutics Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PYC Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PYC Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
29.77x
PYC Therapeutics Ltd's market cap is 29.77 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $97.96 Million | $1.08K | -$3.98 Million | 91039.36x | N/A |
| 2017 | $163.29 Million | $2.76 Million | -$1.95 Million | 59.11x | N/A |
| 2018 | $114.27 Million | $48.46K | -$7.43 Million | 2358.04x | N/A |
| 2019 | $257.19 Million | $250.00 | -$4.08 Million | 1028773.98x | N/A |
| 2020 | $615.98 Million | $2.40 Million | -$6.82 Million | 257.12x | N/A |
| 2021 | $563.79 Million | $3.07 Million | -$17.77 Million | 183.38x | N/A |
| 2022 | $288.17 Million | $16.04 Million | -$13.86 Million | 17.96x | N/A |
| 2023 | $459.41 Million | $15.81 Million | -$22.79 Million | 29.06x | N/A |
| 2024 | $557.83 Million | $22.06 Million | -$37.73 Million | 25.29x | N/A |
| 2025 | $699.40 Million | $23.49 Million | -$50.30 Million | 29.77x | N/A |
Competitor Companies of PYC by Market Capitalization
Companies near PYC Therapeutics Ltd in the global market cap rankings as of May 2, 2026.
Key companies related to PYC Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
PYC Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, PYC Therapeutics Ltd's market cap moved from $53.08 Million to $ 517.68 Million, with a yearly change of 24.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$517.68 Million | -25.98% |
| 2025 | AU$699.40 Million | +25.38% |
| 2024 | AU$557.83 Million | +21.42% |
| 2023 | AU$459.41 Million | +59.42% |
| 2022 | AU$288.17 Million | -48.89% |
| 2021 | AU$563.79 Million | -8.47% |
| 2020 | AU$615.98 Million | +139.50% |
| 2019 | AU$257.19 Million | +125.07% |
| 2018 | AU$114.27 Million | -30.02% |
| 2017 | AU$163.29 Million | +66.70% |
| 2016 | AU$97.96 Million | +84.55% |
| 2015 | AU$53.08 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of PYC Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $517.68 Million USD |
| MoneyControl | $517.68 Million USD |
| MarketWatch | $517.68 Million USD |
| marketcap.company | $517.68 Million USD |
| Reuters | $517.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PYC Therapeutics Ltd
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more